Oticara

Oticara is pioneering a targeted, physician-delivered treatment for chronic rhinosinusitis (CRS) using a novel intranasal corticosteroid cream. The company's lead program has demonstrated positive Phase 2 results, showing durable symptom improvement in hard-to-treat, post-surgical patients. By localizing a potent steroid directly to the site of disease with a single in-office dose, Oticara aims to maximize efficacy while minimizing systemic exposure and simplifying the treatment regimen. The company is privately held, led by experienced pharmaceutical executives, and is advancing a pipeline that includes both CRS symptom management and post-surgical recovery programs.

Novel intranasal drug delivery platform featuring a semisolid, emulsion-based corticosteroid cream designed for endoscopic, physician-placed administration. It enables precise, sustained local drug delivery to inflamed sinonasal mucosa with minimal systemic exposure.

Oticara competes with standard topical steroids (sprays/irrigations) and oral steroids, but targets patients for whom these have failed. It may face competition from other late-stage biologic therapies (e.g., dupilumab) for severe CRS, but differentiates through its localized, single-dose, procedure-based approach.